X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
male (670) 670
humans (661) 661
index medicus (525) 525
animals (513) 513
female (504) 504
quinuclidines - pharmacology (435) 435
quinuclidines - administration & dosage (416) 416
quinuclidines - therapeutic use (403) 403
middle aged (323) 323
adult (267) 267
pharmacology & pharmacy (264) 264
rats (262) 262
aged (244) 244
quinuclidines - adverse effects (203) 203
treatment outcome (187) 187
vomiting - chemically induced (183) 183
palonosetron (181) 181
dose-response relationship, drug (172) 172
isoquinolines - therapeutic use (167) 167
nausea - chemically induced (164) 164
double-blind (162) 162
antiemetics - therapeutic use (159) 159
vomiting - prevention & control (157) 157
double-blind method (149) 149
mice (149) 149
oncology (147) 147
solifenacin succinate (142) 142
nausea - prevention & control (136) 136
nausea (134) 134
isoquinolines - administration & dosage (128) 128
piperidines - pharmacology (128) 128
antineoplastic agents - adverse effects (117) 117
neurokinin-1 receptor antagonists (114) 114
chemotherapy (113) 113
efficacy (110) 110
prevention (110) 110
cancer (107) 107
muscarinic antagonists - administration & dosage (107) 107
time factors (107) 107
drug therapy, combination (104) 104
ondansetron (102) 102
medicine & public health (101) 101
antiemetics - administration & dosage (99) 99
moderately emetogenic chemotherapy (98) 98
quinuclidines - pharmacokinetics (96) 96
muscarinic antagonists - therapeutic use (93) 93
dexamethasone (91) 91
neurosciences (91) 91
vomiting (89) 89
rats, wistar (84) 84
drug therapy (82) 82
care and treatment (81) 81
isoquinolines - adverse effects (79) 79
pulmonary disease, chronic obstructive - drug therapy (79) 79
urinary bladder, overactive - drug therapy (78) 78
rats, sprague-dawley (77) 77
safety (76) 76
quinuclidines - metabolism (75) 75
tetrahydroisoquinolines - administration & dosage (75) 75
muscarinic antagonists - adverse effects (74) 74
phase-iii (74) 74
analysis (72) 72
substance-p (72) 72
prospective studies (71) 71
serotonin antagonists - therapeutic use (70) 70
tetrahydroisoquinolines - therapeutic use (70) 70
vomiting - drug therapy (69) 69
aged, 80 and over (68) 68
overactive bladder (68) 68
drug combinations (67) 67
young adult (64) 64
chemotherapy-induced nausea and vomiting (63) 63
administration, oral (62) 62
dexamethasone - therapeutic use (62) 62
neoplasms - drug therapy (62) 62
quality of life (62) 62
receptor antagonist (61) 61
drug administration schedule (60) 60
administration, inhalation (59) 59
adolescent (59) 59
nausea - drug therapy (59) 59
research (59) 59
chemotherapy-induced nausea (58) 58
pain medicine (57) 57
respiratory system (57) 57
trial (57) 57
antiemetics - adverse effects (56) 56
antineoplastic combined chemotherapy protocols - adverse effects (56) 56
dexamethasone - administration & dosage (55) 55
disease models, animal (55) 55
dogs (55) 55
aprepitant (54) 54
solifenacin (54) 54
pharmacokinetics (52) 52
tetrahydroisoquinolines - adverse effects (52) 52
health care sciences & services (51) 51
nursing (51) 51
copd (50) 50
cross-over studies (50) 50
dosage and administration (50) 50
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1031) 1031
Russian (35) 35
German (16) 16
French (12) 12
Japanese (9) 9
Chinese (7) 7
Italian (3) 3
Hungarian (2) 2
Bulgarian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 05/2018, Volume 378, Issue 18, pp. 1671 - 1680
The frequency of COPD exacerbations during treatment with a triple inhaler — delivering a long-acting beta-agonist (LABA), a long-acting muscarinic antagonist... 
MEDICINE, GENERAL & INTERNAL | OBSTRUCTIVE PULMONARY-DISEASE | IMPACT | PARALLEL-GROUP | DOUBLE-BLIND | TIOTROPIUM | RANDOMIZED CONTROLLED-TRIAL | FLUTICASONE PROPIONATE/SALMETEROL | SALMETEROL | Glucocorticoids - administration & dosage | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Muscarinic Antagonists - adverse effects | Benzyl Alcohols - administration & dosage | Hospitalization - statistics & numerical data | Male | Dyspnea - etiology | Quinuclidines - administration & dosage | Chlorobenzenes - administration & dosage | Adrenergic beta-Agonists - administration & dosage | Adult | Female | Bronchodilator Agents - adverse effects | Adrenergic beta-Agonists - adverse effects | Glucocorticoids - adverse effects | Double-Blind Method | Drug Administration Schedule | Administration, Inhalation | Pulmonary Disease, Chronic Obstructive - complications | Muscarinic Antagonists - administration & dosage | Androstadienes - administration & dosage | Intention to Treat Analysis | Quality of Life | Dyspnea - drug therapy | Aged | Drug Combinations | Pulmonary Disease, Chronic Obstructive - drug therapy | Treatment outcome | Lung diseases, Obstructive | Care and treatment | Usage | Analysis | Diagnosis | Inhalers | Pneumonia | Acetylcholine receptors (muscarinic) | Glucocorticoids | Lung diseases | Critical care | Fluticasone | Patients | Quality of life | Medicine | Hospitals | Obstructive lung disease | Population | Chronic obstructive pulmonary disease | Drug dosages | Life Sciences | Human health and pathology | Pulmonology and respiratory tract
Journal Article
Supportive Care in Cancer, ISSN 0941-4355, 6/2013, Volume 21, Issue 6, pp. 1655 - 1663
Olanzapine has been shown to be a safe and effective agent for the prevention of chemotherapy-induced nausea and vomiting (CINV). Olanzapine may also be an... 
Breakthrough nausea and emesis | Pain Medicine | Chemotherapy | Nursing | Rehabilitation Medicine | Olanzapine | Medicine & Public Health | Oncology | Metoclopramide | Nursing Management/Nursing Research | PREVENTION | APREPITANT | PROPHYLAXIS | ANTIEMETIC ACTIVITY | CANCER-PATIENTS | INDUCED EMESIS | CISPLATIN | ONCOLOGY | HEALTH CARE SCIENCES & SERVICES | DOUBLE-BLIND | REHABILITATION | PALONOSETRON | QUALITY-OF-LIFE | Cyclophosphamide - administration & dosage | Isoquinolines - adverse effects | Nausea - chemically induced | Humans | Middle Aged | Antiemetics - administration & dosage | Dexamethasone - adverse effects | Male | Antineoplastic Agents - administration & dosage | Cyclophosphamide - adverse effects | Quinuclidines - administration & dosage | Cisplatin - administration & dosage | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Antiemetics - adverse effects | Female | Nausea - drug therapy | Vomiting - prevention & control | Quinuclidines - adverse effects | Doxorubicin - administration & dosage | Dexamethasone - administration & dosage | Double-Blind Method | Morpholines - administration & dosage | Metoclopramide - administration & dosage | Vomiting - drug therapy | Neoplasms - drug therapy | Nausea - prevention & control | Vomiting - chemically induced | Metoclopramide - adverse effects | Cisplatin - adverse effects | Benzodiazepines - administration & dosage | Aged | Benzodiazepines - adverse effects | Isoquinolines - administration & dosage | Doxorubicin - adverse effects | Care and treatment | Cyclophosphamide | Anthracyclines | Dexamethasone | Nausea | Cancer | Side effects | Drug therapy | Vomiting | Index Medicus
Journal Article
Journal Article
Expert Review of Respiratory Medicine, ISSN 1747-6348, 06/2014, Volume 8, Issue 3, pp. 357 - 379
Journal Article
Expert Opinion on Pharmacotherapy, ISSN 1465-6566, 02/2017, Volume 18, Issue 3, pp. 283 - 293
Introduction: Inhaled corticosteroids (ICS) alone or in combination with an inhaled long-acting beta 2 -agonist (LABA) are the preferred long-term treatment... 
theophylline | CXCR2 antagonist | agonist | inhaled corticosteroid | Asthma | modulator | statin | phosphodiesterase inhibitor | selective glucocorticoid receptor | long-acting beta | protein kinase inhibitor | long-acting muscarinic antagonist | CRTH2 antagonist | macrolide | ADULT PATIENTS | ALLERGEN CHALLENGE RESPONSE | AIRWAY INFLAMMATION | LUNG-FUNCTION | REVERSES CORTICOSTEROID INSENSITIVITY | ADD-ON THERAPY | MURINE MODEL | ORAL CRTH2 ANTAGONIST | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | long-acting beta-agonist | MILD PERSISTENT ASTHMA | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Asthma - metabolism | Anti-Asthmatic Agents - therapeutic use | Small Molecule Libraries - administration & dosage | Humans | Long-Term Care | Muscarinic Antagonists - therapeutic use | Adrenal Cortex Hormones - therapeutic use | Quinuclidines - administration & dosage | Quinuclidines - therapeutic use | Tiotropium Bromide - administration & dosage | Leukotriene Antagonists - administration & dosage | Phosphodiesterase 4 Inhibitors - administration & dosage | Asthma - immunology | Tiotropium Bromide - therapeutic use | Drug Therapy, Combination | Leukotriene Antagonists - therapeutic use | Macrolides - administration & dosage | Small Molecule Libraries - therapeutic use | Administration, Inhalation | Phosphodiesterase 4 Inhibitors - therapeutic use | Clinical Trials as Topic | Asthma - drug therapy | Drug Discovery | Muscarinic Antagonists - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Anti-Asthmatic Agents - administration & dosage | Macrolides - therapeutic use | Adrenal Cortex Hormones - administration & dosage
Journal Article
Journal Article
Respiratory Medicine, ISSN 0954-6111, 2013, Volume 107, Issue 10, pp. 1538 - 1546
Summary Study objective To examine the efficacy and safety of the once-daily, inhaled, long-acting muscarinic antagonist/β2 -agonist combination... 
Pulmonary/Respiratory | Muscarinic antagonist | Long-acting bronchodilator | β-agonist | Randomised | Fixed-dose combination | COPD | INDACATEROL | LUNG | CARDIAC & CARDIOVASCULAR SYSTEMS | DYSPNEA | BRONCHODILATION | SPIROMETRY | COMBINATION | REFERENCE VALUES | SAMPLE | OBSTRUCTIVE PULMONARY-DISEASE | RESPIRATORY SYSTEM | TIOTROPIUM | beta-agonist | Bronchodilator Agents - therapeutic use | Bronchodilator Agents - administration & dosage | Forced Expiratory Volume - drug effects | Humans | Middle Aged | Benzyl Alcohols - administration & dosage | Benzyl Alcohols - adverse effects | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Benzyl Alcohols - therapeutic use | Quinuclidines - administration & dosage | Chlorobenzenes - administration & dosage | Vital Capacity - drug effects | Quinuclidines - therapeutic use | Female | Bronchodilator Agents - adverse effects | Drug Therapy, Combination | Quinuclidines - adverse effects | Severity of Illness Index | Double-Blind Method | Drug Administration Schedule | Treatment Outcome | Chlorobenzenes - adverse effects | Chlorobenzenes - therapeutic use | Quality of Life | Aged | Drug Combinations | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | Confidence intervals | Smooth muscle | Chronic obstructive pulmonary disease | Drug therapy | Drug dosages
Journal Article
Supportive Care in Cancer, ISSN 0941-4355, 2/2016, Volume 24, Issue 2, pp. 675 - 682
Olanzapine is effective in chemotherapy-induced nausea and vomiting (CINV). In patients receiving highly emetogenic chemotherapy (HEC), its efficacy was... 
Pain Medicine | Nursing | Rehabilitation Medicine | Olanzapine | Medicine & Public Health | Antiemetic therapy | Oncology | Highly-emetogenic chemotherapy | Cisplatin | Nursing Management/Nursing Research | Chemotherapy-induced nausea and vomiting | ORAL NEUROKININ-1 ANTAGONIST | EMETOGENIC CHEMOTHERAPY | DELAYED EMESIS | RELIEF | THERAPY | ONCOLOGY | HEALTH CARE SCIENCES & SERVICES | DOUBLE-BLIND | REHABILITATION | PLACEBO-CONTROLLED TRIAL | HIGH-DOSE CISPLATIN | QUALITY-OF-LIFE | Serotonin Antagonists - administration & dosage | Prospective Studies | Nausea - chemically induced | Humans | Middle Aged | Antiemetics - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Quinuclidines - administration & dosage | Cisplatin - administration & dosage | Genital Neoplasms, Female - drug therapy | Adult | Female | Nausea - drug therapy | Vomiting - prevention & control | Dexamethasone - administration & dosage | Morpholines - administration & dosage | Vomiting - drug therapy | Nausea - prevention & control | Vomiting - chemically induced | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cisplatin - adverse effects | Benzodiazepines - administration & dosage | Aged | Isoquinolines - administration & dosage | Usage | Care and treatment | Chemotherapy | Dexamethasone | Clinical trials | Nausea | Cancer | Studies | Vomiting
Journal Article
European Urology, ISSN 0302-2838, 2013, Volume 64, Issue 6, pp. 1003 - 1012
Journal Article
Journal Article
Annals of Oncology, ISSN 0923-7534, 06/2015, Volume 26, Issue 6, pp. 1248 - 1253
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2017, Volume 35, Issue 31, pp. 3558 - 3565
Journal Article